RBSA Indian Pharma
RBSA Indian Pharma
RBSA Indian Pharma
Pharmaceutical Sector
Contents
Background of Indias Pharmaceutical Industry
Current Trends and Performance
Valuation Multiples Analysis
Regulatory Issues
Industrys Major Players Performance
Contact Us
Valuation
Investment Banking
Advisory Services
1
Drivers of Growth
High Burden
of diseases
Low Cost
destination
(with rising
medical tourism
possibilities)
Higher
Disposable
Income
Improvement
in Healthcare
Infrastructure
Vaccine market
expected to
grow at 20% p.a.
in next decade
Improved
Healthcare
Financing
Over 160,000 hospital beds expected to be added each year in the next decade
14
(USD Bn)
11.6
12
10
4.3
0
FY 2012
FY 2017
Medical Equipment
The medical technology segment has tremendous potential. This potential is being recognized by the
government and there have been many initiatives to promote the sector. In the Union Budget 2012-2013,
customs duty has been reduced from 16 percent to 8 percent for medical and veterinary furniture. The sector is
expected to grow at a CAGR of 13.4 percent with a Market size of USD 4,957.8 million by 2016 as per IBEF
Research.
Formulations
Bulk drugs (active pharmaceutical
ingredients API)
CAGR 14-17%
US $ ~ 23 Billion
Growth
FY2020
Market Size
Domestic
US $ ~
12 Billion
12%
Projected
FY 2013
Indian Pharmaceutical
Industry
Pharma
Export
US $ ~
11 Billion
27%
Historical
90%
Generics
Patented Products
Bulk Drug/ API: According to Indian research journal, out of the total number of pharmaceutical manufacturers,
about 77% produce formulations, while the remaining 23% manufacture bulk drugs.
Global pharma firms have been under significant pressure to reduce prices due to limited growth opportunities in
their home markets, dwindling product pipelines, and regulatory constraints. These factors are pushing foreign firms
to look for growth outside their home markets.
India is seen as a attractive market for the global pharma firms because of its billion plus population, increasing GDP
& per capita income, growing incidence of lifestyle diseases and greater coverage of medical insurance.
Due to the above two reasons , pharma MNCs are willing to pay a significant premium for high-quality pharma assets
in India. Thus, the Indian pharma industry is attracting premium valuation from the MNC`s.
Acquirer
Target
Sector
Stake
Mylan
Agila Specialities
Pharmaceuticals
NA
USD 1.6 Mn
Transasia
Healthcare
NA
USD 6.5 Mn
Trivitron Healthcare
Ani Labsystems
Healthcare
NA
INR 110 Cr
Shalby Hospitals
Krishna Hospitals
Healthcare
86.00%
INR 75 Cr
Mylan
SMS Pharmaceuticals
Pharmaceuticals
NA
USD 33 Mn
Mitsui & Co
Arch Pharmalabs
Pharmaceuticals
25.00%
INR 372 Cr
Hospira Inc.
Pharmaceuticals
NA
Healthcare
NA
Sun Pharmaceutical
Taro Pharma
Pharmaceuticals
Cosme Farma
Healthcare
NA
Healthcare
NA
INR 224 Cr
Piramal Healthcare
Pharmaceuticals
NA
USD 635 Mn
Strides Arcolab
Pharmaceuticals
NA
INR 125 Cr
Origio A/s
Trivector Scientific
Healthcare
51.00%
USD 3.3 Mn
Aanjaneya
Pharmaceuticals
NA
INR 250 Cr
Buy-Out
Size
USD 200 Mn
USD 61 Mn
USD571
INR 70.8 Cr
18%
16%
14%
12%
10%
8%
6%
4%
2%
0%
16.19%
12.25%
11.41%
11.03%
11.28%
8.51%
Margin Comparison
PAT Margin
46%
45%
42%
40%
35%
30%
37%
33%
31%
29%28%
26%
25%24%
25%
20%
40%40%
21%
24%
18%
17%17%
13%13%
15%
22%
19%
21%
14%
13%
13%
11%
10%
5% 6%
5%
0%
Glaxosmith
Pharma
Dr Reddy's Labs
EBITDA Margin 2012
Lupin
Sun Pharma.Inds.
Elder Pharma
Divi's Lab
Cadila Healthcare
7.00 x
Glaxosmit
Divi`s Lab
6.00 x
EV/Sales
5.00 x
4.00 x
Cadila
3.00 x
Lupin
Dr Reddy
2.00 x
Elder Pharma
1.00 x
0.00 x
10%
15%
20%
25%
30%
EBIDTA Margin
35%
40%
45%
EV/ EBIDTA
8.65 x
Industry Average
8.99 x
14.96 x
Cadila Healthcare
15.37 x
15.18 x
Divi's Lab
13.65 x
Sun Pharma:
On account of impressive revenue and profit
growth, benefits from overseas acquisitions,
currency depreciation and healthy sales of its newly
launched drugs, Sun Pharma commands premium
valuation compared to others.
2012
5.71 x
Elder Pharma
6.69 x
17.58 x
Sun
Pharma.Inds.
Divis Lab:
The EBITDA margins have remained constant due to
better gross margins (indicating superior sales mix),
lower employee costs and other expenses
compared to its peers. Thus, the operational
efficiency of Divis lets it command premium
valuation.
2013
15.54 x
12.51 x
Lupin
17.11 x
11.21 x
Dr Reddy's Labs
12.91 x
Glaxosmith
Pharma
19.34 x
27.81 x
PE Multiple
13.63 x
Industry Average
15.90 x
21.94 x
Cadila Healthcare
22.85 x
21.69 x
Divi's Lab
19.09 x
Sun Pharma:
Sun Pharma has the highest market capitalization
amongst its peers. The PE ratio of Sun Pharma has
increased compared to FY 12 because of its
improvement in sequential growth and also a sharp
increase of 63% YoY in its export business, which
contributed close to 57% to its sales.
2013
7.18 x
Elder Pharma
2012
9.62 x
24.25 x
Divi's Lab:
Divi's earns strong margins due to its global cost
and market leadership in some APIs (global market
share of 50-70%), pricing power and strong
backward integration. Due to promising growth
prospect in near future Divis Lab PE ratio is greater
than FY 12.
Sun Pharma.Inds.
GlaxoSmith Pharma:
Despite significant increase in the EBIDTA and PAT
margins of Glaxosmith Pharma, there has been a
fall in its PE multiple which indicates that the stock
is undervalued.
Dr Reddy's Labs
19.84 x
21.00 x
Lupin
26.66 x
19.65 x
22.92 x
33.00 x
Glaxosmith Pharma
45.27 x
Elder Pharma:
The high interest cost burden and overall negative
sentiment in the stock market about the company
management has led to reduction in the P/E
multiple in FY 13.
Cadila :
The reduction in operating efficiency and increase
in depreciation has led to marginal reduction in the
P/E multiple in FY 13.
Note: All Financial data for calculation of multiple has been taken from public sources, annual reports or Capital Line.
Pricing Policy
Pricing Policy
National pharma pricing policy 2012 (NPPP) replaces the
long standing Drugs Price Control Order 1995. The new
policy regulates prices of essential drugs (formulations) as
prescribed in National List of Essential Medicines (NLEM)
and would not regulate the bulk drug manufacturer.
The current regulation fixes the ceiling price of
formulations through Market Based pricing, which earlier
was Cost Based pricing.
Compulsory
Licensing
International
Regulation
Regulations
Budgetary
FDI
Clinical Trials
Compulsory Licensing
A compulsory licence is a provision under the Indian Patent Act which allows the government to mandate a
generic drug maker to produce inexpensive medicine in public interest even when the patent on product is valid.
This provision provides a flexibility on patent protection included in the World Trade Organization's agreement on
intellectual property.
This section allows any one who feels that the drug covered under the patent is 1) Not available to the public at a
reasonable cost 2) does not meet the requirements of the public or 3) is not sufficiently worked in India, can
appeal for compulsory license.
Recent ruling of the Supreme Court & IPAB upholding compulsory licensing has cleared the way for
production of generic drugs in India.
Intellectual Property Appellate Board (IPAB)
Supreme Court.
4
3.23
3
2
1.1
1
0.209
0
FY 2011
FY 2012
Medical education & AIIMS like institutes has been allocated INR 6,377 crores to improve medical education,
training and research
Clinical Trials
The government is now starting to develop an infrastructure for clinical trials in India, with amendments made
recently to Schedule Y of the Drugs and Cosmetics Rules of 1945. Among other developments, Good Clinical
Practice guidelines have been published and made mandatory.
US: A Number of patent would expire in the US during the years 2013-2015,
opportunities on account of patent expiries will amount to around USD125bn
as per India Rating.
The patent expirations, and also healthcare reforms initiated by the US
Government, are likely to provide impetus to growth in the generics market.
Europe: In Europe, most Governments have implemented austerity measures
reducing healthcare spending, this will benefit the overall generic companies.
Source: India Rating
A large number of domestic players are seeking international regulatory approvals from agencies like USFDA, MHRA UK, EMA European Union, TGA Australia and MCC South Africa in order to export their products,
mostly generics, in these markets. A large number of Indian firms are increasingly seeking at least WHO GMP
approval in order to compete for exports to CIS countries and other Asian markets.
India has over 120 USFDA - approved and 84 UK MHRA approved
manufacturing facilities, thus providing a better reach to US & European market.
20%
15%
10%
INR in
Crores
5%
0%
-5%
-10%
BSE Healthcare
11238.89
10000
8019.49
8000
5727.9
3674.72
4000
2000
Sun Phama
12000
6000
BSE Index
4695.4
3494.34
2972.73
2314.68
1907.37
0
FY 2011
FY 2012
EBITDA
FY 2013
PAT
50%
45%
40%
35%
30%
25%
20%
15%
10%
5%
0%
46%
40%
42%
FY 2011
31%
37%
33%
FY 2012
PAT Margin (%)
FY 2013
EBITDA Margin (%)
11
4.00%
10,000
8,000
7,435.20
6,000
2,823.30
4,000
2,000
1,613.20
998.90
2,436.60
1,300.90
1,526.80
0
FY 2011
FY 2012
EBITDA
0.00%
-2.00%
-4.00%
-6.00%
BSE Healthcare
BSE Index
Dr. Reddy
-8.00%
12,000
2.00%
FY 2013
PAT
30%
25%
25%
22%
24%
20%
15%
10%
13%
13%
13%
5%
0%
FY 2011
FY 2012
FY 2013
EBITDA Margin (%)
12
8.00%
4.00%
11,832.60
12,000
9,761.10
10,000
8,000
2,000
-2.00%
-4.00%
BSE Healthcare
BSE Index
Lupin
-6.00%
7,435.20
6,000
4,000
0.00%
14,000
2.00%
2,436.60
1,613.20
998.90
2,823.30
1,526.80
1,300.90
0
FY 2011
FY 2012
FY 2013
EBITDA
PAT
30%
25%
21%
21%
24%
20%
15%
10%
14%
15%
13%
5%
0%
FY 2011
PAT Margin (%)
FY 2012
FY 2013
13
INR in
Crores
BSE Healthcare
2650.54
2414.40
2151.06
1,500
500
Glaxo
2,000
1,000
BSE Index
-8.00%
3,000
2,500
-6.00%
863.36
852.53
625.54
560.57
561.88
428.59
0
FY Dec 2010
FY Dec 2011
FY Dec 2012
EBITDA
PAT
40%
35%
30%
32%
26%
25%
20%
21%
26%
15%
18%
10%
5%
0%
FY Dec 2010
FY Dec 2011
FY Dec 2012
14
1316.55
859.97
747.31
429.27
500
602.01
533.26
0
FY 2011
FY 2012
Total Net Sales
Divis
1864.04
528.04
BSE Index
2139.9
2,000
1,000
BSE Healthcare
2,500
1,500
14%
12%
10%
8%
6%
4%
2%
0%
-2%
-4%
-6%
-8%
FY 2013
EBITDA
PAT
45%
40%
40%
40%
40%
35%
30%
25%
28%
33%
29%
20%
15%
10%
5%
0%
FY 2011
PAT Margin (%)
FY 2012
FY 2013
15
15.00%
10.00%
5.00%
0.00%
-10.00%
BSE Healthcare
5,263.30
4,630.60
4,000
3,000
1,000
Cadila
-15.00%
6,155.38
6,000
2,000
BSE Index
7,000
5,000
-5.00%
1,039.30
736.10
1,162.69
1,137.00
691.73
681.20
0
FY 2011
Total Net Sales
FY 2012
EBITDA
FY 2013
PAT
25%
22%
22%
20%
19%
15%
16%
11%
13%
10%
5%
0%
FY 2011
FY 2012
FY 2013
16
25%
20%
15%
10%
5%
0%
-5%
-10%
INR in
Crores
30%
-15%
BSE Healthcare
BSE Index
Elder Pharma
1,600
1454.28
1334.78
1,400
1,200
1,000
965.28
800
600
400
200
246.19
81.31
227.06
174.65
63.55
72.26
0
FY 2011
Total Net Sales
FY 2012
EBITDA
FY 2013
PAT
in
17%
18%
17%
7%
5%
6%
FY 2011
PAT Margin (%)
FY 2012
FY 2013
EBITDA Margin (%)
17
Glossary
AIIMS
All-India Institute of Medical Sciences
API
Active Pharmaceutical Ingredients
ANDA
Abbreviated New Drug Applications
BV
Book Value
Bn / bn
Billion (s)
CAGR
Compounded Annual Growth Rate
CIS
Commonwealth of Independent States
Capex
Capital Expenditure
EBITDA
Earnings before interest, tax, depreciation and amortization
EBIT
Earnings before interest and tax
EMA
The European Medical Agency
EV
Enterprise Value
GCP
Good Clinical Practice
GDP
Gross Domestic Product
GMP
Good Manufacturing Practice
IBEF
Indian Brand Equity Foundation
ICRA
An associate of Moody`s Investor service(formerly Investment Information
and Credit Rating Agency)
INR
Indian National Rupees
IPAB
Intellectual Property Appellate Board
Mn.
Million(s)
Market Cap Market capitalization
MAT
Minimum Alternate Tax
MCC
Medicines Control Council
MHRA-UK Medicines and Healthcare products Regulatory Agency
MI
Minority Interest
n/a
Data either not applicable or not available
n.p.
Data not provided
NAV
Net Asset Value
NLEM
National List of Essential Medicines
NPPP
National pharma pricing policy 2012
No
Number of
PSAI
Pharmaceutical Services and Active Ingredients
PAT
Profit after tax
ROW
Rest of the World
SEZ
Special Economic Zone
TGA
Therapeutic Goods Administration
UK
The United Kingdome
US
The United States of America
USD
United States Dollar
US-FDA
United States- Food and Drugs Administration
WHO
World Health Organization.
Note: All Financial data for calculation of multiple has been taken from public sources, annual reports or Capital Line,
18
Contact Us
INDIA OFFICES:
Mumbai Office:
21-23, T.V. Industrial Estate, 248-A,
S.K. Ahire Marg, Off. Dr. A. B. Road,
Worli, Mumbai 400 030
Tel : +91 22 2494 0150-54
Fax: +91 22 2494 0154
Delhi Office :
602, Ashoka Estate,
24 Barakhambha Road,
New Delhi 110 001
Tel : +91 11 2335 0635
Bangalore Office:
Unit No.:116, Level I,
Prestige Centre Point,
Cunningham Road,
Bangalore 560 052
Tel : +91 97243 43842
Ahmedabad Office:
912, Venus Atlantis Corporate Park,
Anand Nagar Rd, Prahaladnagar,
Ahmedabad 380 015
Tel : +91 79 4050 6000
Fax : +91 79 4050 6001
Surat Office:
37, 3rd Floor, Meher Park,
A, Athwa Gate, Ring Road,
Surat 395 001
Tel : +91 261 246 4491
Fax : +91 261 301 6366
Jaipur Office:
Karmayog, A-8, Metal Colony,
Sikar Road,
Jaipur 302 023
Tel : +91 141 233 5892
Fax : +91 141 233 5279
Bahrain Office :
Villa # 901, Road 5631, Block 356,
Manama,
Kingdom of Bahrain
Tel: +973 3848 3439
Tel: +91 90040 50600
Dubai Office :
PO Box 32665
Suite: 1801, City Tower 2,
Sheikh Zayed Road, Dubai
Tel: +971 5 5478 6464
Tel: +91 90040 50600
Contact:
Tel: +91 90040 50600
Tel: +971 5 5478 6464
Email: [email protected]
www.rbsa.in
Disclaimer :
To the extent this report relates to information prepared by RBSA Advisors, it is furnished to the recipient for advertising and
general information purposes only. This report and other research material may also be found on our website at www.rbsa.in.
Each recipient should conduct its own investigation and analysis of any such information contained in this report. No recipient is
entitled to rely on the work of RBSA contained in this report for any purpose. RBSA makes no representations or warranties
regarding the accuracy or completeness of such information and expressly disclaims any and all liabilities based on such
information or on omissions there from
19